The Christopher Klebanoff Lab: Publications


Visit PubMed for a full listing of Christopher A. Klebanoff’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

Cruz, A.C., Ramaswamy, M., Ouyang, C., Klebanoff, C.A. et al. Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction. Nature Commun., 7: 13895, 2016.

Klebanoff, C.A. and Restifo, N.P. Customizing functionality and payload delivery for receptor-engineered T cells. Cell, 167: 304-306, 2016.

Eil, R., Vodnala, S.K., Clever, D., Klebanoff, C.A., et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature, 537: 539-543, 2016.

Clever, D., Roychoudhuri, R., Constantinides, M.G., Askenase, M.H., Sukumar, M., Klebanoff, C.A., et al. T cell-intrinsic oxygen-sensing proteins establish the lung as an immunologically permissive metastatic niche. Cell, 166: 1117-1131, 2016.

Roychaudhuri, R., Eil, R.L., Clever, D., Klebanoff, C.A., et al. The transcription factor BACH2 promotes tumor immunosuppression. Journal of Clinical Investigation, 126: 599-604, 2016.

Klebanoff, C.A., Scott, C.D., Leonardi, A.J., Yamamoto, T., et al. Memory T cell–driven differentiation of naive cells impairs adoptive immunotherapy. Journal of Clinical Investigation, 126: 318-334, 2016.

Klebanoff, C.A., Rosenberg, S.A., Restifo, N.P. Prospects of gene-engineered T cell immunotherapy for solid cancers. Nature Medicine, 22: 26-36, 2016.

Klebanoff, C.A., Spencer, S., Torabi-Parizi, P., et al. Retinoic acid controls the homeostasis of pre-cDC derived splenic and intestinal dendritic cells. Journal of Experimental Medicine, 210: 1961-76, 2013.

Gattinoni L.*, Klebanoff C.A.*, Restifo N.P. Paths to stemness: building the ultimate anti-tumour T cell.  Nature Reviews Cancer, 12: 671-84, 2012. * = equal contribution.

Klebanoff C.A., et al.  Determinants of successful CD8+ T cell adoptive immunotherapy for large established tumors in mice. Clinical Cancer Research, 17: 5343-52, 2011.

Klebanoff C.A., Yu Z., Hwang L.N., Palmer D.C., Gattinoni L., Restifo N.P.  Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood, 114: 1776-83, 2009.

Klebanoff, C.A., Gattinoni, L., Torabi-Parizi, P., et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory CD8+ T cells.  Proceedings of the National Academy of Science, 102: 9571-76, 2005.

Klebanoff, C.A., Finkelstein S.E., Surman, D.R., Lichtman, M.K., Gattinoni, L., Grewal, N., Spiess, P.J., Antony, P.A., Palmer, D.C., Tagaya, Y., Rosenberg, S.A., Waldmann, T.A., Restifo, N.P.  IL-15 Enhances the In Vivo Anti-tumor Activity of CD8+ T Cells. Proceedings of the National Academy of Science; 101: 1969-74, 2004.